文献速递胰腺与胆道疾病

利用嘌呤失衡靶向KRAS突变胰腺腺癌

Exploiting a purine imbalance to target KRAS mutant pancreatic adenocarcinomas
RSS 订阅 · Gut (BMJ)

本文探讨靶向Ras家族癌蛋白信号在肿瘤学中的挑战,指出RAS突变是胰腺导管腺癌(PDAC,90–95%)、非小细胞肺癌(30%)和结直肠癌(40%)等预后不良肿瘤的常见驱动因素。PDAC转移性疾病标准治疗5年生存率低于3%,选择性突变RAS抑制剂面临反馈再激活或等位基因切换导致的快速耐药,临床疗效有限。文章强调需识别将RAS通路抑制与靶向嘌呤失衡等化合物整合的联合治疗策略。

要点

  • RAS突变驱动PDAC(90–95%)、NSCLC(30%)和CRC(40%)等预后不良肿瘤。
  • PDAC转移性疾病标准治疗5年生存率低于3%。
  • 选择性突变RAS抑制剂因反馈再激活或等位基因切换出现快速耐药,PDAC疗效有限。

核心结论

  • 靶向RAS信号仍面临挑战,需探索联合治疗策略以克服耐药和PDAC微环境限制。

主要发现

  • RAS突变在PDAC中占90–95%,NSCLC中占30%,CRC中占40%。
  • PDAC转移性疾病标准治疗5年生存率低于3%。
  • 选择性突变RAS抑制剂因反馈再激活或等位基因切换出现快速耐药,PDAC临床疗效有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeting signalling by the rat sarcoma virus (Ras) family of oncoproteins remains one of the biggest challenges in oncology, with RAS mutations being prevalent drivers of tumours of poor prognosis such as pancreatic ductal adenocarcinoma (PDAC, 90–95%), non-small cell lung cancer (30%) or colorectal cancer (40%). 1 The prognosis is particularly bad in the case of pancreatic ductal adenocarcinoma (PDAC), with 5-year survival for metastatic disease remaining under 3% with standard therapies. 2 Despite the very much awaited development of selective inhibitors targeting mutant RAS, these have unfortunately been confronted with rapid resistance due to feedback reactivation or allele switching, and their clinical efficacy in PDAC has been modest. 3 Furthermore, other aspects of PDAC such as its abundant and complex stroma significantly limit the impact of monotherapies. This highlights the need to identify combinatorial therapeutic strategies which integrate RAS pathway inhibition with compounds targeting an...

来源:Gut (BMJ),查看原文。版权归原作者所有。

引用

  1. Gut (BMJ):Exploiting a purine imbalance to target KRAS mutant pancreatic adenocarcinomas

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。